Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan plus Bevacizumab for NSCLC Brain Metastases
NCT06401824Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06401824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401824.